{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T21:53:06Z","timestamp":1781992386717,"version":"3.54.5"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.resinv.2016.03.001","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T20:10:51Z","timestamp":1462047051000},"page":"376-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients"],"prefix":"10.1016","volume":"54","author":[{"given":"Tamao","family":"Nakashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Motojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2016.03.001_bib1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1378\/chest.12-0741","article-title":"Diagnosis and treatment of connective tissue disease-associated interstitial lung disease","volume":"143","author":"Vij","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2016.03.001_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3899\/jrheum.110014","article-title":"Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JASMR study","volume":"38","author":"Kameda","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.resinv.2016.03.001_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/s10165-011-0510-z","article-title":"Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.resinv.2016.03.001_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.resinv.2016.03.001_bib5","doi-asserted-by":"crossref","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.resinv.2016.03.001_bib6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.resinv.2016.03.001_bib7","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"Schiff","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.resinv.2016.03.001_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archinternmed.2007.59","article-title":"Progressive preclinical interstitial lung disease in rheumatoid arthritis","volume":"168","author":"Gochuico","year":"2008","journal-title":"Arch. Intern. Med."},{"issue":"8","key":"10.1016\/j.resinv.2016.03.001_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/RHU.0000000000000084","article-title":"Abatacept therapy in rheumatoid arthritis with interstitial lung disease","volume":"20","author":"Mera-Varela","year":"2014","journal-title":"J. Clin. Rheumatol."}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221253451600037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221253451600037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T12:20:54Z","timestamp":1536754854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221253451600037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S221253451600037X"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2016.03.001","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2016.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}